Torp S H, Helseth E, Dalen A, Unsgaard G
Institute of Cancer Research, Medical Technical Centre, Trondheim, Norway.
Acta Neurochir (Wien). 1992;117(3-4):182-6. doi: 10.1007/BF01400618.
The aim of this study was to determine possible relationships between Ki-67 labelling index (Ki-67 LI), amplification of the epidermal growth factor receptor (EGFR) gene, and prognosis in human glioblastomas. Ki-67 LI was determined on cryosections of biopsy specimens of 20 human glioblastomas with a mouse anti-human Ki-67 monoclonal antibody. Amplification of the EGFR gene was determined by slot blot and Southern blot analyses of DNA extracted from the tumour biopsies. The Ki-67 LI was higher in the glioblastoma group with EGFR gene amplification (8 tumours, median value of Ki-67 LI 4.2, range 0.4-24.6) than in those without EGFR gene amplification (12 tumours, median value of Ki-67 LI 0.8, range 0.2-11.8) (0.05 p less than 0.1). The glioblastoma patients with Ki-67 LI greater than 1.5 (10 tumours) had a statistically significant shorter survival than those with Ki-67 LI less than 1.5 (10 tumours) (p less than 0.05). The glioblastoma patients with EGFR gene amplification lived shorter time than those without EGFR gene amplification (p greater than 0.05).
本研究的目的是确定人胶质母细胞瘤中Ki-67标记指数（Ki-67 LI）、表皮生长因子受体（EGFR）基因扩增与预后之间的可能关系。使用小鼠抗人Ki-67单克隆抗体，对20例人胶质母细胞瘤活检标本的冰冻切片进行Ki-67 LI测定。通过对肿瘤活检提取的DNA进行狭缝印迹和Southern印迹分析来确定EGFR基因的扩增情况。EGFR基因扩增的胶质母细胞瘤组（8个肿瘤，Ki-67 LI中位数为4.2，范围为0.4 - 24.6）的Ki-67 LI高于无EGFR基因扩增的组（12个肿瘤，Ki-67 LI中位数为0.8，范围为0.2 - 11.8）（0.05 < p < 0.1）。Ki-67 LI大于1.5的胶质母细胞瘤患者（10个肿瘤）的生存期在统计学上显著短于Ki-67 LI小于1.5的患者（10个肿瘤）（p < 0.05）。EGFR基因扩增的胶质母细胞瘤患者的生存时间短于无EGFR基因扩增的患者（p > 0.05）。
